Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists in Private Practice in the U.S.

Articles with lock require a subscription to GLG News | Request a free trial
January 7, 2008
Wrong test results = wrong treatment recommendations
Analysis of: Bad Cancer Tests Drawing Scrutiny | online.wsj.com
Author: GLG Expert Contributor
Oncologists rely heavily on hormone and HER-2 status to guide treatment recommendations for women with breast cancer.  If the results of these important tests are incorrect up to 20% of the time, we may be suboptimally treating many breast cancer patients.
January 2, 2008
Erbitux in Lung cancer: new competitor for Avastin?
Analysis of: Randomized Phase II Study of Gemcitabine Plus Cisplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Medical oncologists have "maxed out" on  chemo combinations in lung cancer.  It is clear that biologic agents need to be incorporated into our treatment regimens in order to move forward. Erbitux is safer and can be used in a broader population of lung cancer patients than Avastin.
Taral PatelDecember 7, 2007
Avastin in breast cancer
Analysis of: F.D.A. Criticizes Avastin Use for Breast Cancer | www.nytimes.com
Author: Taral Patel, Oncologist, Mid Ohio Oncology Hematology Inc.
“On face value the data look very good,” said Buzdar, who voted with the slim (5-4) majority against the drug. In the study that was the basis of Genentech’s application, Avastin appeared to slow the progress of the disease. advanced breast cancer who had already tried other drugs. He said he’s never...
Brian AbbottNovember 19, 2007
The Vidaza survival benefit news is a positive for MGI Pharma's Dacogen
Analysis of: Vidaza vs Dacgoen for MDS | www.newratings.com
Author: Brian Abbott, Medical Director of Hematology, Big Sky Oncology
There is no reason to believe Dacogen is inferior to Vidaza. In some studies, Dacogen seems to produce a deeper quality of response, and may also prove more beneficial in AML.
Brian AbbottNovember 19, 2007
Revlimid benefits seem overstated in non-5Q minus MDS
Analysis of: Phase II study of lenalidomide in transfusion-dependent, low- and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q | bloodjournal.hematologylibrary.org
Author: Brian Abbott, Medical Director of Hematology, Big Sky Oncology
Revlimid benefits are often over-stated in non-5Q minus MDS. The cost is a hurdle for many patients with poor prescription plans. Vidaza and Dacogen seem superior in my experience for higher risk patients.
November 6, 2007
Too little, too late
Analysis of: ADVENTRX Provides Update on Cofactor(R) Program | www.pipelinereview.com
Author: GLG Expert Contributor
CoFactor would have been a great drug 15 years ago.
November 5, 2007
ASTRO 2007: Rapid Arc Efficient, Expensive or both?
Analysis of: Varian's New Rapid Arc Delivery | www.varian.com
Author: GLG Expert Contributor
This article reports on Varian's answer to Tomotherapy which has been gaining some market share in the Radiation Oncology linear accelerator arena. Tomotherapy has a good product but requires a shift in treatment planning technique and complete replacement of hardware. There have been reports about...
October 22, 2007
Article overstates heart risk to some degree, nevertheless important
Analysis of: More Prominence Urged for Heart Risks in Breast Cancer Treatment | www.medpagetoday.com
Author: GLG Expert Contributor
The current understanding of heart risks from chemotherapy does not stop oncologists from giving chemotherapy for early breast cancer in those who need it. Better drugs for preventing relapse are certainly welcome, when they are developed.
October 19, 2007
Just one of a thousand other anti-cancer drugs entering into human studies
Analysis of: Curis, Inc. Announces Initiation of Expansion Cohort in Collaborator Genentech's Phase I Clinical Trial of a Systemically Administered Hedgehog Antagonist | www.pipelinereview.com
Author: GLG Expert Contributor
What are my thoughts?  Not much. This drug has just entered early phase studies and the most that we can make of it is that people can tolerate it.
October 19, 2007
Bristol Myers Squib back on track
Analysis of: US FDA approves Bristol-Myers breast cancer drug | www.reuters.com
Author: GLG Expert Contributor
Ixempra is a new drug with big implications.

Previous Page : 1 2 3 4 5 6 Next31 to 40 of 55

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617